<p>Intervacc</p>
<p>Intervacc AB（公开）今天宣布，其分销合作伙伴 Dechra Pharmaceuticals PLC（&#34;Dechra&#34;）将在芬兰推出 Strangvac，疫苗瓶预计将很快可供交付。这次推出是 Intervacc 与 Dechra 之间长期合作的结果，Dechra 现在有权在芬兰销售 Strangvac。考虑到 Dechra 在芬兰的长期存在和强大的组织能力，这是一种自然的发展。</p>
<p>&#34;Dechra 在芬兰有着悠久而成功的历史，给予 Dechra 在芬兰销售 Strangvac 的机会是我们自然而然的选择。我们期待通过我们的疫苗 Strangvac 接触到更多的兽医和马主，&#34;Intervacc 的首席执行官 Jonas Sohlman 表示。</p>
<p>&#34;我们很高兴将这款创新疫苗添加到我们现有的广泛马用产品系列中，并相信这可以在对抗马传染性咽炎的方式上带来变革，&#34;Dechra Nordics 的马用产品经理 Marie Jakobsen 表示。</p>
<p><strong>如需更多信息，请联系：</strong></p>
<p>Jonas Sohlman，首席执行官</p>
<p>电话：+46 (0) 8 120 10 600</p>
<p>电子邮件：jonas.sohlman@intervacc.se</p>
<p>该信息已于 2025 年 5 月 5 日 13:15 CET 通过上述联系人提交发布。</p>
<p><strong>关于 Strangvac</strong></p>
<p>Strangvac 是一种针对马传染性咽炎的疫苗，已在欧盟、英国、冰岛、挪威和列支敦士登获得销售和营销批准。它已在瑞典、丹麦、英国、法国、德国、比利时、荷兰、奥地利、爱尔兰、波兰和意大利推出。</p>
<p><strong>关于 Dechra</strong></p>
<p>Dechra Pharmaceuticals 是 Intervacc 在除北欧和波罗的海国家以外的欧洲地区 Strangvac 疫苗的独家分销合作伙伴。Dechra 是一家全球兽医药品及相关产品的专业公司，专注于兽医产品的开发、生产、营销和销售。</p>
<p><strong>关于 Intervacc</strong></p>
<p>Intervacc AB（公开）是一家动物健康集团，专注于开发动物疫苗。该公司基于专有技术平台开发和销售针对动物疾病的疫苗，采用融合重组蛋白。Intervacc 的股票在纳斯达克第一北方增长市场上市。</p>
<p><strong>认证顾问的联系信息</strong></p>
<p>Eminova Fondkommission AB</p>
<p>电子邮件：adviser@eminova.se，电话：+46 (0) 8 - 684 211 10</p>
<p>https://news.cision.com/intervacc/r/intervacc-s-distribution-partner-dechra-launches-strangvac-in-finland%2Cc4145119</p>
<p>新闻稿 2025 年 5 月 7 日</p>
<p>https://news.cision.com/intervacc/i/lntervacc-%2Cc3405327</p>

<p>Intervacc AB 宣布其分销合作伙伴 Dechra Pharmaceuticals PLC 将在芬兰推出 Strangvac 疫苗。这是在长期合作的基础上进行的，允许 Dechra 在该国销售 Strangvac。这款疫苗已获得欧盟及其他地区的销售批准，旨在改善对马传染性咽喉炎的防治方法。作为兽药领域的专家，Dechra 对将 Strangvac 纳入其产品系列感到兴奋。此次推出反映了 Dechra 在芬兰的强大市场存在，旨在接触更多的兽医和马主</p>

<p>Intervacc</p>
<div class="lb-trans"><p>Intervacc</p>
</div><p>Intervacc AB (publ) announces today that its distribution partner, Dechra Pharmaceuticals PLC (&#34;Dechra&#34;), will launch Strangvac in Finland and vaccine vials are expected to be available for delivery shortly. This launch is the result of an extended collaboration between Intervacc and Dechra, where Dechra now has the right to sell Strangvac in Finland. This is a natural development given Dechra's long-standing presence and strong organization in Finland.</p>
<div class="lb-trans"><p>Intervacc AB（公开）今天宣布，其分销合作伙伴 Dechra Pharmaceuticals PLC（&#34;Dechra&#34;）将在芬兰推出 Strangvac，疫苗瓶预计将很快可供交付。这次推出是 Intervacc 与 Dechra 之间长期合作的结果，Dechra 现在有权在芬兰销售 Strangvac。考虑到 Dechra 在芬兰的长期存在和强大的组织能力，这是一种自然的发展。</p>
</div><p>&#34;Dechra has a long and successful history in Finland, and it was a natural step for us to give Dechra the opportunity to sell Strangvac in Finland. We look forward to reaching more veterinarians and horse owners with our vaccine Strangvac,&#34; says Jonas Sohlman, CEO of Intervacc.</p>
<div class="lb-trans"><p>&#34;Dechra 在芬兰有着悠久而成功的历史，给予 Dechra 在芬兰销售 Strangvac 的机会是我们自然而然的选择。我们期待通过我们的疫苗 Strangvac 接触到更多的兽医和马主，&#34;Intervacc 的首席执行官 Jonas Sohlman 表示。</p>
</div><p>&#34;We are excited to add this innovative vaccine to our existing broad equine product range and believe this can become a game changer in the approach to strangles&#34; says Marie Jakobsen, Equine Product Manager at Dechra Nordics.</p>
<div class="lb-trans"><p>&#34;我们很高兴将这款创新疫苗添加到我们现有的广泛马用产品系列中，并相信这可以在对抗马传染性咽炎的方式上带来变革，&#34;Dechra Nordics 的马用产品经理 Marie Jakobsen 表示。</p>
</div><p><strong>For</strong> <strong>more information please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，请联系：</strong></p>
</div><p>Jonas Sohlman, CEO</p>
<div class="lb-trans"><p>Jonas Sohlman，首席执行官</p>
</div><p>Phone: +46 (0) 8 120 10 600</p>
<div class="lb-trans"><p>电话：+46 (0) 8 120 10 600</p>
</div><p>E-mail: jonas.sohlman@intervacc.se</p>
<div class="lb-trans"><p>电子邮件：jonas.sohlman@intervacc.se</p>
</div><p>The information was submitted for publication, through the agency of the contact person set out above on May 5, 2025 at 13.15 CET.</p>
<div class="lb-trans"><p>该信息已于 2025 年 5 月 5 日 13:15 CET 通过上述联系人提交发布。</p>
</div><p><strong>About Strangvac</strong></p>
<div class="lb-trans"><p><strong>关于 Strangvac</strong></p>
</div><p>Strangvac, a vaccine against equine strangles, is approved for sale and marketing in the EU, as well as in the United Kingdom, Iceland, Norway, and Liechtenstein. It has been launched in Sweden, Denmark, the United Kingdom, France, Germany, Belgium, the Netherlands, Austria, Ireland, Poland, and Italy.</p>
<div class="lb-trans"><p>Strangvac 是一种针对马传染性咽炎的疫苗，已在欧盟、英国、冰岛、挪威和列支敦士登获得销售和营销批准。它已在瑞典、丹麦、英国、法国、德国、比利时、荷兰、奥地利、爱尔兰、波兰和意大利推出。</p>
</div><p><strong>About Dechra</strong></p>
<div class="lb-trans"><p><strong>关于 Dechra</strong></p>
</div><p>Dechra Pharmaceuticals is the exclusive distribution partner of Intervacc for the Strangvac vaccine in Europe excluding the Nordic and Baltic countries. Dechra is a global specialist in veterinary pharmaceuticals and related products. Dechra has expertise in the development, manufacturing, marketing and sales of high-quality products exclusively for veterinarians worldwide.</p>
<div class="lb-trans"><p>Dechra Pharmaceuticals 是 Intervacc 在除北欧和波罗的海国家以外的欧洲地区 Strangvac 疫苗的独家分销合作伙伴。Dechra 是一家全球兽医药品及相关产品的专业公司，专注于兽医产品的开发、生产、营销和销售。</p>
</div><p><strong>About Intervacc</strong></p>
<div class="lb-trans"><p><strong>关于 Intervacc</strong></p>
</div><p>Intervacc AB (publ) is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on the proprietary technology platform with fused recombinant proteins. The Intervacc share is listed on Nasdaq First North Growth Market.</p>
<div class="lb-trans"><p>Intervacc AB（公开）是一家动物健康集团，专注于开发动物疫苗。该公司基于专有技术平台开发和销售针对动物疾病的疫苗，采用融合重组蛋白。Intervacc 的股票在纳斯达克第一北方增长市场上市。</p>
</div><p><strong>Contact information for Certified Adviser</strong></p>
<div class="lb-trans"><p><strong>认证顾问的联系信息</strong></p>
</div><p>Eminova Fondkommission AB</p>
<div class="lb-trans"><p>Eminova Fondkommission AB</p>
</div><p>E-mail: adviser@eminova.se, Phone: +46 (0) 8 - 684 211 10</p>
<div class="lb-trans"><p>电子邮件：adviser@eminova.se，电话：+46 (0) 8 - 684 211 10</p>
</div><p>https://news.cision.com/intervacc/r/intervacc-s-distribution-partner-dechra-launches-strangvac-in-finland%2Cc4145119</p>
<div class="lb-trans"><p>https://news.cision.com/intervacc/r/intervacc-s-distribution-partner-dechra-launches-strangvac-in-finland%2Cc4145119</p>
</div><p>Press Release 05/07/2025</p>
<div class="lb-trans"><p>新闻稿 2025 年 5 月 7 日</p>
</div><p>https://news.cision.com/intervacc/i/lntervacc-%2Cc3405327</p>
<div class="lb-trans"><p>https://news.cision.com/intervacc/i/lntervacc-%2Cc3405327</p>
</div>

Intervacc 的分销合作伙伴 Dechra 在芬兰推出了 Strangvac 疫苗